Alluvi, formerly BI 4744, represents a notable breakthrough in obesity therapy. This dual stimulator targeting both glucagon-like peptide-1 and GIP targets demonstrates remarkable effectiveness in patient studies, https://one-bookmark.com/story22087273/alluvi-a-comprehensive-dive-into-the-drug-s-potential